A detailed history of Clark Estates Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Clark Estates Inc holds 40,275 shares of GILD stock, worth $3.8 Million. This represents 0.88% of its overall portfolio holdings.

Number of Shares
40,275
Previous 43,575 7.57%
Holding current value
$3.8 Million
Previous $2.99 Million 12.91%
% of portfolio
0.88%
Previous 0.77%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$66.59 - $83.99 $219,747 - $277,167
-3,300 Reduced 7.57%
40,275 $3.38 Million
Q2 2024

Aug 08, 2024

SELL
$63.15 - $72.88 $88,410 - $102,032
-1,400 Reduced 3.11%
43,575 $2.99 Million
Q1 2024

May 07, 2024

SELL
$71.58 - $87.29 $894,750 - $1.09 Million
-12,500 Reduced 21.75%
44,975 $3.29 Million
Q1 2023

May 12, 2023

SELL
$77.31 - $88.08 $844,611 - $962,274
-10,925 Reduced 15.97%
57,475 $4.77 Million
Q3 2022

Nov 14, 2022

SELL
$59.54 - $68.01 $4.05 Million - $4.62 Million
-68,000 Reduced 49.85%
68,400 $4.22 Million
Q1 2021

May 14, 2021

BUY
$60.0 - $68.46 $924,000 - $1.05 Million
15,400 Added 12.73%
136,400 $8.82 Million
Q4 2020

Feb 09, 2021

BUY
$56.65 - $64.55 $3.85 Million - $4.39 Million
68,000 Added 128.3%
121,000 $7.05 Million
Q4 2019

Feb 05, 2020

BUY
$61.62 - $67.78 $394,368 - $433,792
6,400 Added 13.73%
53,000 $3.44 Million
Q3 2019

Nov 12, 2019

BUY
$62.51 - $69.0 $2.91 Million - $3.22 Million
46,600 New
46,600 $2.95 Million
Q2 2019

Aug 01, 2019

SELL
$61.87 - $69.38 $3.07 Million - $3.44 Million
-49,550 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$71.28 - $78.92 $106,920 - $118,380
1,500 Added 3.12%
49,550 $3.83 Million
Q3 2017

Oct 16, 2017

BUY
$72.11 - $85.47 $3.46 Million - $4.11 Million
48,050
48,050 $3.89 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $118B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Clark Estates Inc Portfolio

Follow Clark Estates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clark Estates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Clark Estates Inc with notifications on news.